Showing 20 of 91 recruiting trials for “myelodysplastic-syndrome”
A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
👨⚕️ Linghui Xia, Professor, Department of Hematology, Wuhan Union Hospital, Tongji Medical college, Huazhong University of Science and Technology📍 1 site📅 Started Feb 2023View details ↗
BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
CAV Regimen for R/R AML
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
RecruitingNCT05290662 ↗
Registry of Patients Having Received oNKord®
Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.
RecruitingNCT05326919 ↗
The Patient Cohort of the National Center for Precision Medicine in Leukemia
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML
A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
👨⚕️ Depei Wu, MD. PhD, The First Affiliated Hospital of Soochow University📍 1 site📅 Started Sep 2021View details ↗
SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →